MorphoSys Inks Deal with Pfizer for Use of Slonomics Platform; Ups 2010 Guidance

Per the arrangement, Morphosys will receive an upfront payment of an undisclosed amount this year, with the possibility of annual license fees over the patent lifetime of the Slonomics platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.